123 related articles for article (PubMed ID: 14638557)
21. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery.
Lindenauer PK; Pekow P; Wang K; Gutierrez B; Benjamin EM
JAMA; 2004 May; 291(17):2092-9. PubMed ID: 15126437
[TBL] [Abstract][Full Text] [Related]
22. Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease.
Kawecka-Jaszcz K; Jankowski P; Pajak A
Int J Cardiol; 2003 Sep; 91(1):15-23. PubMed ID: 12957725
[TBL] [Abstract][Full Text] [Related]
23. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.
Steg PG; Iung B; Feldman LJ; Cokkinos D; Deckers J; Fox KA; Keil U; Maggioni AP
Heart; 2002 Jul; 88(1):20-4. PubMed ID: 12067934
[TBL] [Abstract][Full Text] [Related]
24. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis.
Brieger D; D'Souza M; Hyun K; Weaver JC; Kritharides L
Med J Aust; 2019 Feb; 210(2):80-85. PubMed ID: 30712304
[TBL] [Abstract][Full Text] [Related]
25. Persistence of use of lipid-lowering medications: a cross-national study.
Avorn J; Monette J; Lacour A; Bohn RL; Monane M; Mogun H; LeLorier J
JAMA; 1998 May; 279(18):1458-62. PubMed ID: 9600480
[TBL] [Abstract][Full Text] [Related]
26. Strategies for implementing lipid-lowering therapy: pharmacy-based approach.
Birtcher KK; Bowden C; Ballantyne CM; Huyen M
Am J Cardiol; 2000 Feb; 85(3A):30A-35A. PubMed ID: 10695705
[TBL] [Abstract][Full Text] [Related]
27. The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention.
Ma JM; Jackevicius CA; Genus U; Dzavik V
Can J Cardiol; 2006 Apr; 22(5):419-23. PubMed ID: 16639478
[TBL] [Abstract][Full Text] [Related]
28. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.
Majumdar SR; Gurwitz JH; Soumerai SB
J Gen Intern Med; 1999 Dec; 14(12):711-7. PubMed ID: 10632815
[TBL] [Abstract][Full Text] [Related]
29. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.
Yang CC; Jick SS; Testa MA
Br J Clin Pharmacol; 2003 Jul; 56(1):84-91. PubMed ID: 12848779
[TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering therapies in the management of acute coronary syndromes.
Mosca L; Biviano A;
Curr Cardiol Rep; 2002 Jul; 4(4):320-6. PubMed ID: 12052271
[TBL] [Abstract][Full Text] [Related]
31. Royal College of Physicians of Edinburgh Consensus Conference on lipid lowering to prevent vascular events 17 & 18 March 1999.
Scott Med J; 1999 Jun; 44(3):73-4. PubMed ID: 10461692
[No Abstract] [Full Text] [Related]
32. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study.
Bertolotti M; Franchi C; Rocchi MB; Miceli A; Libbra MV; Nobili A; Lancellotti G; Carulli L; Mussi C;
Drugs Aging; 2017 Apr; 34(4):311-319. PubMed ID: 28299634
[TBL] [Abstract][Full Text] [Related]
33. Frequency of lipid-lowering therapy after a coronary event in Helsinki, Finland.
Strandberg TE; Vanhanen H; Tikkanen MJ
Am J Cardiol; 1999 Jul; 84(1):95, A8. PubMed ID: 10404860
[TBL] [Abstract][Full Text] [Related]
34. A new paradigm for plaque stabilization.
Ambrose JA; Martinez EE
Circulation; 2002 Apr; 105(16):2000-4. PubMed ID: 11997290
[TBL] [Abstract][Full Text] [Related]
35. Adherence to lipid-lowering drug therapy among members of the Canadian Forces.
Ma J; Vaillancourt R; Bennett C
Mil Med; 2008 Jul; 173(7):666-70. PubMed ID: 18700601
[TBL] [Abstract][Full Text] [Related]
36. The future: screening and effective intervention.
Brunton SA
Am J Med; 1998 Jun; 104(6A):54S-59S. PubMed ID: 9684853
[TBL] [Abstract][Full Text] [Related]
37. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.
Ramsay LE; Haq IU; Jackson PR; Yeo WW; Pickin DM; Payne JN
Lancet; 1996 Aug; 348(9024):387-8. PubMed ID: 8709740
[No Abstract] [Full Text] [Related]
38. Use of lipid-lowering medication in patients with acute myocardial infarction (Worcester Heart Attack Study).
Goldberg RJ; Ockene IS; Yarzebski J; Savageau J; Gore JM
Am J Cardiol; 1997 Apr; 79(8):1095-7. PubMed ID: 9114770
[TBL] [Abstract][Full Text] [Related]
39. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now.
Fonarow GC; Ballantyne CM
Circulation; 2001 Jun; 103(23):2768-70. PubMed ID: 11401927
[No Abstract] [Full Text] [Related]
40. Pharmacologic prevention of coronary artery disease. What do clinical trials show?
Milani RV; Lavie CJ
Postgrad Med; 1996 Feb; 99(2):109-12, 115-20. PubMed ID: 8632961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
